explore -WSS

explore

author：knowledge 2025-10-08 16:58:29 - browse：6123

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： $1 billion proposal to grow Boston, Massachusetts biotech

Wikipedia

WSS

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Stem cell biologist probes earliest stages of human development

Why Talkspace is targeting Medicare, a tricky market

A public scorecard can help hold safety

In early work, researchers turn to CRISPR to treat Alzheimer's

$1 billion proposal to grow Boston, Massachusetts biotech

Wikipedia

explore

focus

Tori Bowie and the unacceptable rates of Black maternal death

Florida health officials providing scant details on measles cases

Tori Bowie and the unacceptable rates of Black maternal death

The public health thinking behind the CDC’s new Covid guidance

Trump demands the U.S. pay no more for drugs than other countries … again

Sanders adds drug shortage policies to pandemic preparedness bill

Hollywood unions extend contract negotiations for actors

Change Healthcare: What is it, why does its cyberattack matter?

After affirmative action ruling, medical educators look to 'holistic review'

Medicare has a new plan to address drug shortages

hotspot

Group opposing PBM reform sets lobbying record

Biden's 'march

Streamlined flu vaccines recommended by FDA advisory panel

Key House panel plots a new health care package

Immune cells and nerve overgrowth may explain recurring UTI pain

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

knowledge

Wikipedia

Wikipedia

focus